Satellos Bioscience Inc. (TSX: MSCL)
MSCL trades on the Toronto Stock Exchange in Life Sciences, headquartered in Ontario. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of September 30, 2026. US$ figures convert C$ at 1.4263 C$ per US$, the Bank of Canada daily rate for October 14, 2026. Close and returns: Yahoo Finance daily closes for MSCL.TO, last bar 2026-10-14, computed by Sophia Capital.
Profile
| Field | Value |
|---|---|
| Ticker | MSCL on the Toronto Stock Exchange |
| Yahoo symbol | MSCL.TO |
| Sector | Life Sciences |
| Headquarters | Ontario |
| Listed | 2024-02-15 |
| Listing type | TSXV Grad |
| Shares outstanding | 21,216,439 |
| Also listed on | NasdaqGM |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001421642 |
| Website | No company website on record |
| US listing | MSLE |
Returns
| Window | Return |
|---|---|
| 1 day | -4.0% |
| 1 week | -11.8% |
| 1 month | -29.7% |
| 3 months | -25.3% |
| 6 months | -3.9% |
| Year to date | +19.9% |
| 1 year | -1.0% |
| From 52-week high | -46.8% |
| 52-week range | C$7.80 to C$17.85 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
75 documents in 13 types. Each title links to the document at its source.
Annual financial statements (2)
| Document | Type | Filed |
|---|---|---|
| Financial Statements Request Form | Annual financial statements (6-K) | 2026-05-20 |
| Audited Consolidated Financial Statements of the Registrant as of and for the years ended December 31, 2025 and 2024. Period 2025-12-31 | Annual financial statements (40-F) | 2026-03-27 |
Interim financial statements (2)
| Document | Type | Filed |
|---|---|---|
| Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2026 and 2025 (Unaudited) Period 2026-06-30 | Interim financial statements (6-K) | 2026-08-13 |
| Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2026 and 2025 (Unaudited) Period 2026-03-31 | Interim financial statements (6-K) | 2026-05-15 |
MD&A (3)
| Document | Type | Filed |
|---|---|---|
| Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2025. Period 2025-12-31 | MD&A (annual) (40-F) | 2026-03-27 |
| Management’s Discussion and Analysis for the three and six months ended June 30, 2026, and 2025 Period 2026-06-30 | MD&A (interim) (6-K) | 2026-08-13 |
| Management’s Discussion and Analysis for the three months ended March 31, 2026, and 2025 Period 2026-03-31 | MD&A (interim) (6-K) | 2026-05-15 |
Annual information form (1)
| Document | Type | Filed |
|---|---|---|
| Annual Information Form of the Registrant for the fiscal year ended December 31, 2025. Period 2025-12-31 | Annual information form (40-F) | 2026-03-27 |
Material change report (1)
| Document | Type | Filed |
|---|---|---|
| Material Change report dated February 13, 2026 | Material change report (6-K) | 2026-02-17 |
News release (24)
| Document | Type | Filed |
|---|---|---|
| PRESS RELEASE | News release (6-K) | 2026-10-05 |
| PRESS RELEASE | News release (6-K) | 2026-09-30 |
| PRESS RELEASE | News release (6-K) | 2026-09-24 |
| PRESS RELEASE | News release (6-K) | 2026-09-15 |
Management information circular / proxy (3)
| Document | Type | Filed |
|---|---|---|
| Management Information Circular and Notice of | Management information circular (6-K) | 2026-05-20 |
| Form of Proxy | Form of proxy / voting instruction (6-K) | 2026-05-20 |
| Voting Instruction Form | Form of proxy / voting instruction (6-K) | 2026-05-20 |
Report of voting results (1)
| Document | Type | Filed |
|---|---|---|
| Report of Voting Results | Report of voting results (6-K) | 2026-06-17 |
Prospectus (4)
| Document | Type | Filed |
|---|---|---|
| F-10 | Prospectus (short form) (F-10) | 2026-08-11 |
| F-10 | Prospectus (short form) (F-10) | 2026-02-05 |
| SUPPL | Prospectus supplement (SUPPL) | 2026-08-14 |
| SUPPL | Prospectus supplement (SUPPL) | 2026-02-06 |
Annual report (1)
| Document | Type | Filed |
|---|---|---|
| 40-F Period 2025-12-31 | Annual report (40-F) (40-F) | 2026-03-27 |
Early warning / ownership (2)
| Document | Type | Filed |
|---|---|---|
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2026-05-15 |
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2026-05-12 |
Certification (8)
| Document | Type | Filed |
|---|---|---|
| Form 52-109F2 Certification of Interim Filings by CEO | Certification (52-109F2) (6-K) | 2026-08-13 |
| Form 52-109F2 Certification of Interim Filings by CFO | Certification (52-109F2) (6-K) | 2026-08-13 |
| Form 52-109F2 Certification of Interim Filings by CEO | Certification (52-109F2) (6-K) | 2026-05-15 |
| Form 52-109F2 Certification of Interim Filings by CFO | Certification (52-109F2) (6-K) | 2026-05-15 |
Other (23)
| Document | Type | Filed |
|---|---|---|
| Investor Call Presentation | Investor presentation (6-K) | 2026-07-08 |
| EXHIBIT 5.1 | Consent (F-10) | 2026-08-11 |
| Consent of Independent Registered Public Accounting Firm – PricewaterhouseCoopers LLP Period 2025-12-31 | Consent (40-F) | 2026-03-27 |
| EXHIBIT 5.1 | Consent (F-10) | 2026-02-05 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
Trading: the last notice, on 2026-02-06, was a resumption.
| Notice | Action | Reason | Notice |
|---|---|---|---|
| 2026-02-06 9:00 AM ET | Resumption | No reason stated | CIRO notice |
| 2026-02-06 8:38 AM ET | Halt | Dissemination | CIRO notice |
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2025-01-03 | Equity, Option To Acquire, Security To Be Acquired | US$25.0M | US$25.0M | SEC EDGAR |
| 2023-05-25 | Equity, Option To Acquire, Security To Be Acquired | US$33.3M | US$33.3M | SEC EDGAR |
| 2022-09-27 | Equity, Option To Acquire, Security To Be Acquired, Other | US$99K | US$2.1M | SEC EDGAR |
| 2019-09-10 | Equity, Option To Acquire, Security To Be Acquired, Other | US$188K | US$2.5M | SEC EDGAR |
| 2019-03-08 | Equity, Option To Acquire, Security To Be Acquired, Other | US$152K | US$972K | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| AIDX | HealWELL AI Inc. | TSX | C$243.8M | -11.7% | -51.8% |
| TSND | TerrAscend Corp. | TSX | C$235.0M | -26.4% | -40.2% |
| CRDL | Cardiol Therapeutics Inc. | TSX | C$281.9M | -42.2% | +9.6% |
| PAIN | Vector Science and Therapeutics Corp. | TSXV | C$300.3M | -18.4% | Under a year of closes |
| PRN | Profound Medical Corp. | TSX | C$304.9M | +17.1% | +17.5% |
The app has the price chart, every filing, private raises and the full peer set for MSCL.
Open in the app